Audience & Learning Objectives

SGO 2020 Annual Meeting Webinar Series

Target Audience

This meeting is intended for gynecologic oncologists, medical oncologists, radiation oncologists, obstetrician/gynecologists, fellows and residents in these areas, research scientists, nurses, nurse practitioners, physician assistants, allied health professionals and other clinicians involved in the care of patients with gynecologic malignancies.

Learning Objectives

Webinar #1: Novel Discoveries in Endometrial Cancer: Are we finally making progress?

  1. Review the efficacy and tolerability of the addition of the anti-diabetic drug metformin to paclitaxel/carboplatin in endometrial cancer patients.
  2. Summarize dostarlimab safety and efficacy data for patients with deficient mismatch repair endometrial cancer from the GARNET trial.
  3. Summarize the role of trastuzumab in the treatment of women with advanced or recurrent uterine, HER2+ serous carcinoma.
  4. Describe the observed activity of adavosertib in recurrent uterine serous carcinoma

 

Webinar #2: Paradigm Changes in Front Line Ovarian Cancer

  1. Describe the continuum of benefit to niraparib across homologous recombination subgroups in the PRIMA/OV-26/GOG-3012 trial of patients with newly diagnosed ovarian cancer.
  2. Describe outcomes of secondary endpoints from the PRIMA/OV-26/GOG-3012
  3. Demonstrate the efficacy and tolerability of maintenance therapy with olaparib plus bevacizumab versus bevacizumab alone in patients with advanced high-grade ovarian cancer in response to first-line platinum-based chemotherapy plus bevacizumab.
  4. Demonstrate the efficacy of maintenance therapy with olaparib plus bevacizumab according to surgical timing and residual disease in women with advanced high-grade ovarian cancer in response to first-line platinum-based chemotherapy plus bevacizumab.
  5. Present the results of a population-adjusted indirect treatment comparison that used data from the Phase III SOLO1 and PAOLA-1 trials to assess the comparative efficacies of maintenance therapies from these trials in patients with newly diagnosed advanced BRCA-mutated ovarian cancer.
  6. Demonstrate the role of veliaparib in the treatment of primary advanced ovarian cancer
  7. Delineate clearly the objective response rates observed in patients treated with veliparib in combination with chemotherapy

 

Webinar #3: Rare Tumors

  1. Describe the activity of single agent MEK inhibition with the oral MEK inhibitor binimetinib vs physicians choice of chemotherapy in patients with recurrent low grade serous ovarian cancer.
  2. Review the findings of GOG 0281 sponsored by NRG Oncology.
  3. Describe the activity of enzalutamide in androgen receptor positive low grade serous and high grade serous ovarian cancer.
  4. Identify anti-tumor activity of pembrolizumab in women with high grade neuroendocrine cancers of the vulva and cervix
  5. Describe the findings of this Phase 2 study in this important patient population (PRmCC), evaluating the addition of Lm vaccine to PD-L1 therapy.
  6. Describe the safety of combination of checkpoint inhibitor, cisplatin and pelvic RT

 

Webinar #4: Molecular testing and patient selection in ovarian cancer: How Do We Optimize PROs?

  1. Describe the tolerability of PARP inhibitor and platinum chemotherapy in patients with ovarian cancer overall and in biomarker-selected subsets.
  2. Conclude that HRD score is not a predictive biomarker of Veliparib benefit in 1L ovarian cancer
  3. Define the role of PARP inhibitors in monotherapy in treatment of platinum sensitive ovarian cancer.
  4. Summarize the effect of rucaparib vs placebo on postprogression endpoints in a post hoc exploratory analysis of the subgroup of patients with a non-BRCA homologous recombination repair (HRR) gene mutation in their tumor who participated in the phase 3 study ARIEL3 (NCT01968213).

 

Webinar #5: Surgical Innovations in Gynecologic Cancers

  1. Describe the performance characteristics of sentinel lymph node biopsy using indocyanine green in stage I high-grade endometrial cancer patients
  2. Identify the new surgical standard of care for women with early stage vulvar cancer
  3. Define the role of radiotherapy in pts with SN mets < 2 mm
  4. Describe the significance of MM or ITCs found on otherwise negative lymph nodes towards the risk of recurrance in early stage endometrioid adenocarcinoma of the uterus.
  5. Describe the patient and disease characteristics associated with isolated tumor cells and micrometastasis diagnosis on sentinel lymph node biopsy performed for endometrial cancer staging

 

Webinar #6: Front Line Ovarian Cancer: Turning up the Heat on Immunotherapy

  1. Describe the results from the first phase 3 trial of a checkpoint inhibitor (avelumab; anti–PD-L1) in patients with previously untreated epithelial ovarian cancer.
  2. Identify opportunities of dual targeted vaccines for ovarian cancer maintenance stratified by BRCA status
  3. Summarize the efficacy and safety of niraparib + bevacizumab combination therapy in patients with ovarian cancer after response to front-line platinum-based chemotherapy.
  4. Describe the toxicities and the effect on the tumor microenvironment of adding nivolumab to upfront carboplatin and paclitaxel
  5. Describe trends in use of heated intraperitoneal chemotherapy (HIPEC) in ovarian cancer treatment after publication of van Driel et al’s “HIPEC in Ovarian Cancer” was published in January 2018. Compare associated rates of hospital-based outcomes, including length of stay, intensive care unit admission, complications, and costs, in ovarian cancer patients who underwent surgery with or without HIPEC.
  6. Describe the comparative outcomes of type of chemotherapy regimen used at time of HIPEC.
  7. Summarize perioperative outcomes in women with advanced epithelial ovarian cancer (EOC) undergoing interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) via minimally invasive interval debulking surgery (MIIDS) or laparotomy (LAP).
  8. Demonstrate insertion of HIPEC probes via minimally invasive surgical incision.

 

Webinar #7: Genetic Discoveries and Pathologic Variations in Ovarian Cancer

  1. Identify two groups of postmenopausal BRCA1 mutation carriers that differ by histopathological criteria and relate the phenotype to tumor-promoting properties
  2. Identify the utility of transcriptomic analysis of primary patient samples to better characterize tumor differences.
  3. Identify the impact of single cell technologies in ovarian cancer
  4. Demonstrate that tumor-tissue testing represents a reliable, feasible and cost-saving screening-procedure for BRCA mutational status assessment.
  5. Illustrate the complexity of BRCA1 mediated platinum response in ovrian cancer
  6. Describe how homologous recombination gene mutation frequencies compare between USCs and HGSOCs
  7. Identify pertinent deleterious germline mutations present in fallopian tube carcinomas, as they compare to those seen in ovarian and primary peritoneal carcinomas and demonstrate how this had changed over time with the adoption of serial fallopian tube sectioning.

 

Webinar #8: Developmental Therapeutics in Gynecologic Cancer

  1. Identify tumor genomic markers that may predict response to PLD based therapies
  2. Describe tumoral changes in PD-L1 modified proportion score and immune environment after exposure to pembrolizumab
  3. Demonstrate the effect an IL-15 superagonist (N-803) has on the immune microenvironment in the peritoneal cavity and peripheral blood when administered weekly as maintenance therapy in a Phase II clinical trial.
  4. Describe the safety and efficacy of CAR T cells targeting muc16ecto in ovarian cancer
  5. Review the safety and efficacy of XMT-1536, an ADC targeting NaPi2b

Top